Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021)
Century Therapeutics' (IPSC) quarterly Preferred Stock Liabilities came in at $159.6 million in Q1 2021, up 357.1% on a QoQ basis from $34.9 million in Q4 2020.
Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Century Therapeutics (IPSC) has 2 years of Preferred Stock Liabilities data on file, last reported at $159.6 million in Q1 2021.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $159.6 million in Q1 2021; TTM through Mar 2021 was $159.6 million, a N/A change from a year earlier, with the FY2020 full-year figure at $34.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2021 stood at $159.6 million, up from $34.9 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for IPSC reached as high as $159.6 million in Q1 2021 and fell as low as $34.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Century Therapeutics | 406.30 Mn | 271.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 159.63 Mn |
| Dec 31, 2020 | 34.92 Mn |
| Sep 30, 2020 | 34.99 Mn |
| Jun 30, 2020 | 34.99 Mn |